Диссертация (Факторы риска формирования неблагоприятных исходов хронического гепатита С), страница 21

– № 4. – P. 1279.134. Lok A., Everhart J., Wright E. et al. Maintenance Peginterferon Therapy andOther Factors Associated With Hepatocellular Carcinoma in Patients WithAdvanced Hepatitis C // Gastroenterology – 2011. – Vol. 140. – № 3. – P. 840849.135. Lok A., Seeff L., Morgan T. et al. Incidence of hepatocellular carcinoma andassociated risk factors in hepatitis C-related advanced liver disease //Gastroenterology – 2009. – Vol.

136. – № 1. – P. 138-148.136. Lok A., Sterling R., Everhart J. et al. Des-gamma-carboxy prothrombin andalpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma// Gastroenterology – 2010. – Vol. 138. – № 2. – P. 493-502.137.

Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis forthe Global Burden of Disease Study 2010 // Lancet (London, England) – 2012. –Vol. 38.0 – № 9859. – P. 2095-2128.138. Mallet V., Gilgenkrantz H., Serpaggi J. et al.

Brief communication: therelationship of regression of cirrhosis to outcome in chronic hepatitis C // Ann.Intern. Med. – 2008. – Vol. 149. – № 6. – P. 399-403.139. Marco V., Almasio P., Ferraro D. et al. Peg-interferon alone or combined withribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial// J. Hepatol.

– 2007. – Vol. 47. – № 4. – P. 484-491.140. Marrero J., Fontana R., Fu S. et al. Alcohol, tobacco and obesity aresynergistic risk factors for hepatocellular carcinoma // J. Hepatol. – 2005. – Vol.42. – № 2. – P. 218-224.141. Martin-Carbonero L., Ledinghen V., Moreno A. et al. Liver fibrosis in131patients with chronic hepatitis C and persistently normal liver enzymes: influenceof HIV infection // J. Viral Hepat.

– 2009. – Vol. 16. – № 11. – P. 790-795.142. Martino V., Rufat P., Boyer N. et al. The influence of humanimmunodeficiency virus coinfection on chronic hepatitis C in injection drug users:a long-term retrospective cohort study // Hepatology – 2001. – Vol. 34. – № 6. – P.1193-1199.143. Mashitani T., Yoshiji H., Yamazaki M. et al. Development of hepatocellularcarcinoma in a patient 13 years after sustained virological response to interferonagainst chronic hepatitis C: a case report // Cases J.

– 2009. – Vol. 2. – № 1. – P.18.144. Meer A., Feld J., Hofer H. et al. Risk of cirrhosis-related complications inpatients with advanced fibrosis following hepatitis C virus eradication // J.Hepatol. – 2017. - Vol. 66. – № 3. – P. 485-493.145. Meer A., Veldt B., Feld J. et al. Association Between Sustained VirologicalResponse and All-Cause Mortality Among Patients With Chronic Hepatitis C andAdvanced Hepatic Fibrosis // JAMA – 2012. – Vol.

308. – № 24. – P. 2584-2593.146. Modi A., Feld J., Park Y. et al. Increased caffeine consumption is associatedwith reduced hepatic fibrosis // Hepatology – 2010. – Vol. 51. – № 1. – P. 201209.147. Morgan R., Baack B., Smith B. et al. Eradication of hepatitis C virus infectionand the development of hepatocellular carcinoma: a meta-analysis of observationalstudies // Ann. Intern. Med.

– 2013. – Vol. 158. – № 5. – P. 329-337.148. Mueller S., Millonig G., Seitz H. et al. Alcoholic liver disease and hepatitis C:a frequently underestimated combination // World J. Gastroenterol. – 2009. – Vol.15. – № 28. – P. 3462-3471.149. Mutimer D., Aghemo A., Diepolder H. et al. EASL Clinical PracticeGuidelines: Management of hepatitis C virus infection // J.

Hepatol. – 2014. – Vol.60. – № 2. – P. 392-420.150. Nahon P., Kettaneh A., Lemoine M. et al. Liver stiffness measurement inpatients with cirrhosis and hepatocellular carcinoma: a case-control study // Eur. J.132Gastroenterol. Hepatol. – 2009. – Vol. 21. – № 2.– P. 214-219.151. Nahon P., Sutton A., Rufat P. et al. A variant in myeloperoxidase promoterhastens the emergence of hepatocellular carcinoma in patients with HCV-relatedcirrhosis // J.

Hepatol. – 2012. – Vol. 56. – № 2. – P. 426-432.152. Naing C., Mak J., Ahmed S. et al. Relationship between hepatitis C virusinfection and type 2 diabetes mellitus: meta-analysis // World J. Gastroenterol. –2012. – Vol. 18. – № 14. – P. 1642-1651.153. Negro F. HCV infection and metabolic syndrome: which is the chicken andwhich is the egg? // Gastroenterology – 2012. – Vol.

142. – № 6. – P. 1288-1292.154. Nguyen M., Garcia R., Simpson P. et al. Racial differences in effectiveness ofalpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C viruscirrhosis // Hepatology – 2002. – Vol. 36. – № 2. – P. 410-417.155.

Nishiguchi S., Kuroki T., Nakatani S. et al. Randomised trial of effects ofinterferon-alpha on incidence of hepatocellular carcinoma in chronic activehepatitis C with cirrhosis // Lancet (London, England) – 1995. – Vol. 346. – №8982. – P. 1051-1055.156. Nishiguchi S., Shiomi S., Nakatani S. et al. Prevention of hepatocellularcarcinoma in patients with chronic active hepatitis C and cirrhosis // Lancet –2001. – Vol.

35.7 – № 9251. – P. 196-197.157. Nkontchou G., Bastard J.-P., Ziol M. et al. Insulin resistance, serum leptin,and adiponectin levels and outcomes of viral hepatitis C cirrhosis // J. Hepatol. –2010. – Vol. 53. – № 5. – P. 827-833.158. Ogawa E., Furusyo N., Kajiwara E. et al. Efficacy of pegylated interferonalpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patientswith chronic hepatitis C: a prospective, multicenter study // J. Hepatol.

– 2013. –Vol. 58. – № 3. – P. 495-501.159. Ostapowicz G., Watson K., Locarnini S. et al. Role of alcohol in theprogression of liver disease caused by hepatitis C virus infection // Hepatology –1998. – Vol. 27. – № 6. – P. 1730-1735.160. Otani K., Korenaga M., Beard M. et al. Hepatitis C virus core protein,133cytochrome P450 2E1, and alcohol produce combined mitochondrial injury andcytotoxicity in hepatoma cells // Gastroenterology – 2005. – Vol. 128. – № 1.

– P.96-107.161. Park M., Han K.-H., Kim S. et al. Non-invasive prediction of development ofhepatocellular carcinoma using transient elastography in patients with chronic liverdisease // Expert Rev. Gastroenterol. Hepatol. – 2014. – Vol. 8. – № 5. – P. 501511.162. Pekow J., Bhan A., Zheng H. et al. Hepatic steatosis is associated withincreased frequency of hepatocellular carcinoma in patients with hepatitis Crelated cirrhosis // Cancer – 2007. – Vol. 109. – № 12. – P. 2490-2496.163. Perez-Latorre L., Sanchez-Conde M., Rincon D. et al. Prediction of LiverComplications in Patients With Hepatitis C Virus-Related Cirrhosis With andWithout HIV Coinfection: Comparison of Hepatic Venous Pressure Gradient andTransient Elastography // Clin.

Infect. Dis. – 2014. – Vol. 58. – № 5. – P. 713-718.164. Persico M., Bruno S., Costantino A. et al. The impact of antiviral therapy andthe influence of metabolic cofactors on the outcome of chronic HCV infection //Int. J. Hepatol. – 2011. – Vol. 2011. – P. 314-301.165. Pessione F., Degos F., Marcellin P.

et al. Effect of alcohol consumption onserum hepatitis C virus RNA and histological lesions in chronic hepatitis C //Hepatology – 1998. – Vol. 27. – № 6. – P. 1717-1722.166. Petta S., Di Marco V., Bruno S. et al. Impact of virus eradication in patientswith compensated hepatitis C virus-related cirrhosis: competing risks andmultistate model // Liver Int. – 2016.167. Pineda J., García-García J., Aguilar-Guisado M.

et al. Clinical progression ofhepatitis C virus-related chronic liver disease in human immunodeficiency virusinfected patients undergoing highly active antiretroviral therapy // Hepatology –2007. – Vol. 46. – № 3. – P. 622-630.168. Pineda J., Romero-Gómez M., Díaz-García F. et al. HIV coinfection shortensthe survival of patients with hepatitis C virus-related decompensated cirrhosis //Hepatology – 2005. – Vol. 41.

– № 4. – P. 779-789.134169. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosisprogression in patients with chronic hepatitis C. The OBSVIRC, METAVIR,CLINIVIR, and DOSVIRC groups // Lancet (London, England) – 1997. – Vol.349. – № 9055. – P. 825-832.170. Raimondi S., Bruno S., Mondelli M. et al.

Hepatitis C virus genotype 1b as arisk factor for hepatocellular carcinoma development: a meta-analysis // J. Hepatol.– 2009. – Vol. 50. – № 6. – P. 1142-1154.171. Ramos-Casals M., Robles A., Brito-Zerón P. et al. Life-threateningcryoglobulinemia: clinical and immunological characterization of 29 cases //Semin. Arthritis Rheum. – 2006. – Vol. 36. – № 3. – P. 189-196.172.

Re V., Kallan M., Tate J. et al. Hepatic decompensation in antiretroviraltreated patients co-infected with HIV and hepatitis C virus compared with hepatitisC virus-monoinfected patients: a cohort study // Ann. Intern. Med. – 2014. – Vol.160. – № 6. – P. 369-379.173. Retamozo S., Díaz-Lagares C., Bosch X. et al.

Life-ThreateningCryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of279 Patients // Medicine (Baltimore). – 2013. – Vol. 92. – № 5. – P. 273-284.174. Rincón D., Lo Iacono O., Tejedor M. et al. Prognostic value of hepatic venouspressure gradient in patients with compensated chronic hepatitis C-related cirrhosis// Scand. J. Gastroenterol.

– 2013. – Vol. 48. – № 4. – P. 487-495.175. Rincon D., Ripoll C., Lo Iacono O. et al. Antiviral therapy decreases hepaticvenous pressure gradient in patients with chronic hepatitis C and advanced fibrosis// Am. J. Gastroenterol. – 2006. – Vol. 101. – № 10. – P.